Vanguard (NYSE: CHRS holder) discloses 8.29% Coherus Oncology stake after realignment

Rhea-AI Filing Summary

The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 10,028,893 shares of Coherus Oncology Inc common stock, representing 8.29% of the class. Vanguard reports no sole voting or dispositive power, with 815,663 shares subject to shared voting power and 10,028,893 shares subject to shared dispositive power.

Vanguard explains that an internal realignment on January 12, 2026 means certain subsidiaries or business divisions are expected to report holdings separately on a disaggregated basis, while pursuing the same investment strategies as before. The holdings include securities in the form of rights, and Vanguard states its clients have the right to receive dividends or sale proceeds, with no single other person’s interest exceeding 5%. Vanguard certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Coherus Oncology Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

19249H103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 19249H103

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 815,663.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 10,028,893.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,028,893.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.29 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. The holdings reported herein include securities in the form of rights.The CUSIP Number listed throughout this filing is the CUSIP assigned to the Ordinary Shares of the Issuer.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coherus Oncology Inc
(b)	Address of issuer's principal executive offices: 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 19249H103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 10028893
(b)	Percent of class: 8.29 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 815663
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 10028893
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	01/30/2026

FAQ

What percentage of Coherus Oncology (CHRS) shares does The Vanguard Group report owning?

The Vanguard Group reports beneficial ownership of 8.29% of Coherus Oncology common stock. This represents 10,028,893 shares, including securities in the form of rights, held on behalf of Vanguard’s clients under its investment management and advisory responsibilities.

How many Coherus Oncology (CHRS) shares does Vanguard have voting and dispositive power over?

Vanguard reports shared voting power over 815,663 Coherus shares and shared dispositive power over 10,028,893 shares. It has no sole voting or sole dispositive power, indicating decisions are made jointly within Vanguard’s managed structures.

What internal change at The Vanguard Group is disclosed in this Coherus (CHRS) filing?

Vanguard discloses an internal realignment effective January 12, 2026. After this date, it no longer performs portfolio management or proxy voting, and certain subsidiaries or business divisions are expected to report beneficial ownership separately on a disaggregated basis.

Who ultimately benefits from the Coherus Oncology (CHRS) holdings reported by Vanguard?

Vanguard states that its clients have the right to dividends and sale proceeds from the reported Coherus securities. These clients include registered investment companies and other managed accounts, and no single other person’s interest exceeds 5% of the class.

Is The Vanguard Group seeking to influence control of Coherus Oncology (CHRS)?

Vanguard certifies the Coherus shares are held in the ordinary course of business, not to influence control. It also states the holdings are not connected with any transaction aimed at changing control, other than activities tied to certain nomination rules.

What type of securities and CUSIP are covered in Vanguard’s Coherus (CHRS) Schedule 13G/A?

The filing covers Coherus Oncology common stock under CUSIP 19249H103. Vanguard notes the holdings reported include securities in the form of rights, and that the CUSIP corresponds to the issuer’s ordinary shares.